NATCO Pharma Limited (NATCOPHARM.NS)
INR 775.5
(3.88%)
INR 775.5
(3.88%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 40.02 Billion INR | 47.72% |
| 2022 | 27.07 Billion INR | 42.11% |
| 2021 | 19.04 Billion INR | 12.7% |
| 2020 | 16.9 Billion INR | -10.46% |
| 2019 | 18.87 Billion INR | -8.44% |
| 2018 | 20.61 Billion INR | -4.4% |
| 2017 | 21.56 Billion INR | 5.73% |
| 2016 | 20.39 Billion INR | 81.35% |
| 2015 | 11.24 Billion INR | 37.41% |
| 2014 | 8.18 Billion INR | 12.03% |
| 2013 | 7.3 Billion INR | 12.41% |
| 2012 | 6.5 Billion INR | 25.0% |
| 2011 | 5.2 Billion INR | 18.9% |
| 2010 | 4.37 Billion INR | 1.54% |
| 2009 | 4.3 Billion INR | -1.7% |
| 2008 | 4.38 Billion INR | 33.7% |
| 2007 | 3.27 Billion INR | 35.7% |
| 2006 | 2.41 Billion INR | 43.69% |
| 2005 | 1.68 Billion INR | 8.87% |
| 2004 | 1.54 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 FY | 39.98 Billion INR | 47.72% |
| 2023 Q4 | 13.62 Billion INR | 27.55% |
| 2023 Q1 | 10.31 Billion INR | -9.57% |
| 2023 Q2 | 7.58 Billion INR | -26.45% |
| 2023 Q3 | 10.68 Billion INR | 40.83% |
| 2022 Q3 | 8.97 Billion INR | 82.31% |
| 2022 Q1 | 4.32 Billion INR | -51.15% |
| 2022 Q4 | 11.4 Billion INR | 27.02% |
| 2022 FY | 27.07 Billion INR | 42.11% |
| 2022 Q2 | 4.92 Billion INR | 13.98% |
| 2021 Q3 | 5.56 Billion INR | -0.64% |
| 2021 FY | 19.04 Billion INR | 12.7% |
| 2021 Q1 | 3.77 Billion INR | -8.07% |
| 2021 Q2 | 5.6 Billion INR | 48.59% |
| 2021 Q4 | 8.84 Billion INR | 58.84% |
| 2020 Q1 | 8.02 Billion INR | 42.39% |
| 2020 Q4 | 4.1 Billion INR | 1445.25% |
| 2020 Q3 | -305 Million INR | -108.59% |
| 2020 Q2 | 3.55 Billion INR | -55.72% |
| 2020 FY | 16.9 Billion INR | -10.46% |
| 2019 Q4 | 5.63 Billion INR | 31.76% |
| 2019 FY | 18.87 Billion INR | -8.44% |
| 2019 Q1 | 4.85 Billion INR | -1.34% |
| 2019 Q2 | 4.82 Billion INR | -0.72% |
| 2019 Q3 | 4.27 Billion INR | -11.32% |
| 2018 Q2 | 5.56 Billion INR | 2.43% |
| 2018 Q1 | 5.43 Billion INR | 0.91% |
| 2018 Q4 | 4.92 Billion INR | 16.38% |
| 2018 FY | 20.61 Billion INR | -4.4% |
| 2018 Q3 | 4.23 Billion INR | -24.02% |
| 2017 Q2 | 5.62 Billion INR | 31.76% |
| 2017 Q4 | 5.38 Billion INR | -29.85% |
| 2017 Q3 | 7.67 Billion INR | 36.57% |
| 2017 Q1 | 4.26 Billion INR | -0.33% |
| 2017 FY | 21.56 Billion INR | 5.73% |
| 2016 FY | 20.39 Billion INR | 81.35% |
| 2016 Q1 | 4.15 Billion INR | 39.47% |
| 2016 Q2 | 6.42 Billion INR | 54.83% |
| 2016 Q4 | 4.28 Billion INR | -25.91% |
| 2016 Q3 | 5.77 Billion INR | -10.12% |
| 2015 Q3 | 3.94 Billion INR | 49.89% |
| 2015 Q1 | 2.22 Billion INR | 3.28% |
| 2015 Q4 | 2.97 Billion INR | -24.52% |
| 2015 FY | 11.24 Billion INR | 37.41% |
| 2015 Q2 | 2.63 Billion INR | 18.11% |
| 2014 Q2 | 1.84 Billion INR | -11.86% |
| 2014 Q4 | 2.15 Billion INR | -8.22% |
| 2014 Q3 | 2.35 Billion INR | 27.53% |
| 2014 Q1 | 2.09 Billion INR | 9.75% |
| 2014 FY | 8.18 Billion INR | 12.03% |
| 2013 Q2 | 1.86 Billion INR | 14.28% |
| 2013 Q4 | 1.9 Billion INR | -12.27% |
| 2013 FY | 7.3 Billion INR | 12.41% |
| 2013 Q1 | 1.62 Billion INR | -0.99% |
| 2013 Q3 | 2.17 Billion INR | 16.62% |
| 2012 FY | 6.5 Billion INR | 25.0% |
| 2012 Q3 | 1.83 Billion INR | 16.46% |
| 2012 Q2 | 1.57 Billion INR | -12.5% |
| 2012 Q1 | 1.8 Billion INR | 34.1% |
| 2012 Q4 | 1.64 Billion INR | -10.45% |
| 2011 FY | 5.2 Billion INR | 18.9% |
| 2011 Q2 | 1.29 Billion INR | 2.1% |
| 2011 Q3 | 1.61 Billion INR | 25.15% |
| 2011 Q4 | 1.34 Billion INR | -16.91% |
| 2011 Q1 | 1.26 Billion INR | 0.0% |
| 2010 FY | 4.37 Billion INR | 1.54% |
| 2009 FY | 4.3 Billion INR | -1.7% |
| 2008 FY | 4.38 Billion INR | 33.7% |
| 2007 FY | 3.27 Billion INR | 35.7% |
| 2006 FY | 2.41 Billion INR | 43.69% |
| 2005 FY | 1.68 Billion INR | 8.87% |
| 2004 FY | 1.54 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 34.523% |
| Hester Biosciences Limited | 3.04 Billion INR | -1214.087% |
| Aarti Drugs Limited | 25.28 Billion INR | -58.271% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -120.435% |
| Albert David Limited | 3.62 Billion INR | -1004.117% |
| Alembic Limited | 1.57 Billion INR | -2441.19% |
| Alkem Laboratories Limited | 126.67 Billion INR | 68.408% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -2524.853% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -745.342% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -9896.178% |
| Brooks Laboratories Limited | 794.86 Million INR | -4934.843% |
| Eris Lifesciences Limited | 20.09 Billion INR | -99.189% |
| FDC Limited | 19.42 Billion INR | -105.976% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -75.279% |
| Gufic Biosciences Limited | 8.06 Billion INR | -396.116% |
| Hikal Limited | 17.84 Billion INR | -124.252% |
| Ind-Swift Limited | 5.02 Billion INR | -696.468% |
| Innova Captab Limited | 10.81 Billion INR | -270.108% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | -87.642% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -1817.567% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 40.294% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -589.347% |
| Lupin Limited | 196.56 Billion INR | 79.64% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -989.414% |
| Medico Remedies Limited | 1.44 Billion INR | -2661.51% |
| Morepen Laboratories Limited | 17.01 Billion INR | -135.149% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -137.568% |
| Orchid Pharma Limited | 8.19 Billion INR | -388.425% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -247.619% |
| RPG Life Sciences Limited | 5.82 Billion INR | -587.57% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -2492.431% |
| Sigachi Industries Limited | 3.98 Billion INR | -903.118% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -223.162% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -280.652% |
| Themis Medicare Limited | 3.81 Billion INR | -948.3% |
| Unichem Laboratories Limited | 16.57 Billion INR | -141.46% |
| Vaishali Pharma Limited | 862.79 Million INR | -4538.403% |
| Wanbury Limited | 5.75 Billion INR | -595.214% |
| Windlas Biotech Limited | 6.3 Billion INR | -534.276% |
| ZIM Laboratories Limited | 3.67 Billion INR | -988.929% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -212.437% |
| Ipca Laboratories Limited | 77.05 Billion INR | 48.066% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 91.748% |
| Venus Remedies Limited | 5.91 Billion INR | -576.643% |
| Sakar Healthcare Limited | 1.54 Billion INR | -2495.881% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 86.201% |
| Divi's Laboratories Limited | 78.45 Billion INR | 48.987% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -208.908% |
| Mankind Pharma Limited | 103.34 Billion INR | 61.276% |
| Sequent Scientific Limited | 13.69 Billion INR | -192.174% |
| Laurus Labs Limited | 50.01 Billion INR | 19.989% |
| Neuland Laboratories Limited | 15.58 Billion INR | -156.772% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | -16.078% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 66.122% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 78.961% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -850.074% |
| Wockhardt Limited | 27.89 Billion INR | -43.492% |
| Bal Pharma Limited | 3.39 Billion INR | -1079.767% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 85.664% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -419.575% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -4084.424% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | -138.672% |
| Shilpa Medicare Limited | 11.53 Billion INR | -247.062% |
| Valiant Laboratories Limited | 1.82 Billion INR | -2098.21% |
| Ajanta Pharma Limited | 42.08 Billion INR | 4.911% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -911.582% |
| Granules India Limited | 45.06 Billion INR | 11.192% |
| Medicamen Biotech Limited | 1.79 Billion INR | -2131.936% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -1443.719% |
| Piramal Enterprises Limited | 60.33 Billion INR | 33.673% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 62.265% |
| Suven Life Sciences Limited | 116.92 Million INR | -34125.898% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -7837.09% |
| Strides Pharma Science Limited | 40.51 Billion INR | 1.213% |
| Indoco Remedies Limited | 18.17 Billion INR | -120.218% |
| Alpa Laboratories Limited | 1.08 Billion INR | -3580.372% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -3735.721% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -5197.484% |